VTRS

Mastercard, Cheniere Energy and Viatris shares climbed to annual highs on Thursday amid strong quarterly results and positive company catalysts.

Viatris received FDA approval in October 2026 to expand RYZUMVI ophthalmic solution 0.75% for treating presbyopia in adults, adding to its existing indication for pharmacologically induced mydriasis and supported by a defined safety profile from clinical…

Viatris (VTRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Viatris (NasdaqGS: VTRS) received U.S. FDA approval for RYZUMVI to treat presbyopia in adults in October 2026. RYZUMVI was previously cleared only for pharmacologically induced mydriasis, so the new label adds a second approved use.

ExxonMobil, Baytex Energy and Viatris have risen to 52-week highs amid soaring energy prices and Wall Street optimism around the companies.

Viatris (VTRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Viatris will release its third-quarter earnings next week, and analysts anticipate a single-digit profit dip.

The latest update on Pacira BioSciences lifts the modelled fair value from US$30.00 to about US$33.57 per share, a mid single digit change that reframes where some analysts see the stock settling.

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how generic pharmaceuticals stocks fared in Q2, starting with Viatris (NASDAQ:VTRS).

Viatris Inc. (NASDAQ:VTRS) is a familiar name in the pharmaceutical industry, with a portfolio that stretches from branded medications to generics and fresh, innovative therapies. Its broad reach and diverse lineup help bring in steady revenue year after year.